A phase II study to assess the efficacy of osimertinib in patients with EGFR MT(+)T790M(-) NSCLC

被引：0

作者：

Hayakawa, Daisuke ^{[1
]}

Takeda, Masayuki ^{[2
,3
]}

Shimokawa, Mototsugu ^{[4
]}

Nakamura, Atsushi ^{[5
]}

Nosaki, Kaname ^{[6
]}

Watanabe, Yasutaka ^{[7
]}

Kato, Terufumi ^{[8
]}

Tanaka, Hiroshi ^{[9
]}

Takahashi, Toshiaki ^{[10
]}

Oki, Masahide ^{[11
]}

Tachihara, Motoko ^{[12
]}

Fujimoto, Daichi ^{[13
]}

Yamaguchi, Kakuhiro ^{[14
]}

Hayashi, Hidetoshi ^{[2
]}

Yamamoto, Shoichiro ^{[15
]}

Iwama, Eiji ^{[16
]}

Azuma, Koichi ^{[17
]}

Yamamoto, Nobuyuki ^{[13
]}

Nakagawa, Kazuhiko ^{[2
]}

机构：

[1] Juntendo Univ, Dept Resp Med, Grad Sch Med, Tokyo, Japan

[2] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan

[3] Nara Med Univ, Dept Canc Genom & Med Oncol, Kashihara, Nara, Japan

[4] Yamaguchi Univ, Dept Biostat, Grad Sch Med, Yamaguchi, Japan

[5] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

[6] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[7] Saitama Canc Ctr, Div Thorac Oncol, Saitama, Japan

[8] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan

[9] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan

[10] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[11] Natl Hosp Org Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan

[12] Kobe Univ, Grad Sch, Dept Internal Med, Div Resp Med, Kobe, Hyogo, Japan

[13] Wakayama Med Univ, Internal Med 3, Wakayama, Japan

[14] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan

[15] Ehime Univ, Grad Sch Med, Dept Cardiol Pulmonol Hypertens & Nephr, Ehime, Japan

[16] Kyushu Univ, Dept Resp Med, Grad Sch Med Sci, Fukuoka, Japan

[17] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Dept Internal Med, Kurume, Fukuoka, Japan

[18] Japan Lung Canc Alliance, Yokohama, Kanagawa, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.128

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O7-2

引用

页码：S1387 / S1387

页数：1

共 50 条

[1] ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test
Freitas, H. C.
Park, K.
Kim, D-W.
Tiseo, M.
Hochmair, M. J.
Chang, G-C.
Shi, Y-K.
Moran, T.
Chen, Y.
Laskin, J.
Solomon, B.
Miranda, M.
Rigas, J.
Cheema, P. K.
Kim, S-W.
ANNALS OF ONCOLOGY, 2018, 29 : 149 - 149
[2] Association between BIM Deletion Polymorphism and Efficacy of Osimertinib in Advanced EGFR T790M NSCLC Patients
Li, X.
Zhang, D.
Wang, R. Z.
Li, B.
Guo, M.
Zou, B.
Yu, J.
Wang, L.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E87 - E87
[3] Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
Zhao, S.
Jiang, T.
Li, X.
Zhao, C.
Su, C.
Ren, S.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S410 - S410
[4] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
Remon, Jordi
Caramella, Caroline
Joelet, Cecile
Lacroix, Ludovic
Lawson, Andrew
Smalley, Sarah
Howarth, Karen
Gale, Davina
Rosenfeld, Nitzan
Green, Emma
Plagnol, Vincent
Planchard, David
Bluthgen, Maria
Gazzah, Annas
Pannet, Chloe
Nicotra, Claudio
Soria, Jean-Charles
Besse, Benjamin
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
[5] Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Schmid, S.
Klingbiel, D.
Aeppli, S.
Britschgi, C.
Gautschi, O.
Pless, M.
Rothschild, S.
Wannesson, L.
Janthur, W.
Foerbs, D.
Demmer, I.
Jochum, W.
Fruth, M.
LUNG CANCER, 2019, 130 : 149 - 155
[6] Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
Zhao, Sha
Li, Xuefei
Zhao, Chao
Jiang, Tao
Jia, Yijun
Shi, Jinpeng
He, Yayi
Li, Jiayu
Zhou, Fei
Gao, Guanghui
Li, Wei
Chen, Xiaoxia
Su, Chunxia
Ren, Shengxiang
Zhou, Caicun
LUNG CANCER, 2019, 128 : 33 - 39
[7] Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M
Masuhiro, Kentaro
Shiroyama, Takayuki
Suzuki, Hidekazu
Takata, So
Nasu, Shingo
Takada, Hiromune
Morita, Satomu
Tanaka, Ayako
Morishita, Naoko
Okamoto, Norio
Hirashima, Tomonori
ANTICANCER RESEARCH, 2018, 38 (06) : 3567 - 3571
[8] Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
Zhang, X.
Wu, Y-L.
Chen, Y.
Zhang, H.
Wu, G.
Lu, Y.
Liang, Z.
Hu, Y.
Cheng, Y.
Wang, J.
Ying, J.
Liu, W.
Liang, Z.
ANNALS OF ONCOLOGY, 2022, 33 : S1537 - S1537
[9] A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs
Jiang, R.
Wang, X.
Wang, L.
Huang, D.
Ding, C.
Wang, C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S346 - S347
[10] A Phase II Study of Osimertinib versus Combination of Osimertinib and Chemotherapy for EGFR and T790M-Mutation Positive NSCLC
Mouri, A.
Tanaka, K.
Asahina, H.
Kishimoto, J.
Okada, M.
Watanabe, K.
Hamai, K.
Harada, T.
Tsubata, Y.
Sugawara, S.
Kobayashi, K.
Sugio, K.
Oizumi, S.
Okamoto, I.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S226 - S227

← 1 2 3 4 5 →